Nurix Therapeutics, Inc. NRIX Accrued expenses and other current liabilities
Accrued expenses and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept nrix:AccruedExpensesAndOtherLiabilitiesCurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported accrued expenses and other current liabilities of $59.95M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities increased by 35.1% year-over-year, from $44.36M to $59.95M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s accrued expenses and other current liabilities has grown at a 46.0% compound annual growth rate (CAGR), from $8.28M to $54.85M.
- What does accrued expenses and other current liabilities mean?
- This reflects obligations for goods or services received for which invoices have not yet been processed or payments are not yet due. It captures the short-term operational liabilities that represent the company's ongoing commitment to vendors and service providers.